Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InspireMD Inc NSPR

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.


NDAQ:NSPR - Post by User

Bullboard Posts
Comment by dmacdon Jan 22, 2019 10:32am
196 Views
Post# 29264156

RE:it's a buy today for me

RE:it's a buy today for meAdded more today .. the LINC sessions will drive up the SP ... my expectation anyways. Had to average down after the dilutive financing. Looks like a few prior investor houses gave up or did not like the prior deal. I believe they will regret. I did not like the prior deal either but here is my chance to load up below that deal. Maybe a steal here at the current SP. Let's also see how sales did in Q4 since we need to carry the momentum for the perhaps final placement before profitability in 3 or 4 quarters unless loans become an option at that point. Looking good to me on the tech and acceptance side. The surgeon videos are compelling. We need to see a video showing an actual procedure even if just on a demo or simulation though cadaver with micro camera would be awesome. I want to see how it gets thru the blockage, is fed thru the arterial pathways and gets expanded, then retraction of the guide wire.
Bullboard Posts